Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

scientific article published on 17 March 2009

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1159/000209289
P698PubMed publication ID19293564

P50authorSebastian SchneeweissQ60162120
John D SeegerQ91589185
P2093author name stringRaymond G Schlienger
Shao Zhu
Mike Doherty
Donnie Funch
Carlos Fernandez-Vidaurre
P433issue1
P304page(s)7-21
P577publication date2009-03-17
P1433published inDermatologyQ5262700
P1476titleTopical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma
P478volume219

Reverse relations

cites work (P2860)
Q510998972% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Q52646026A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).
Q35733343Association Between Malignancy and Topical Use of Pimecrolimus
Q39224205CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults.
Q38807878Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.
Q36573102Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study
Q37861867Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.
Q30465036Geographic and climatic factors associated with exfoliation syndrome.
Q37865056Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate
Q38266892Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs
Q28086973Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants
Q34167722Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study
Q36042131Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis
Q89175645Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
Q36892767Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice
Q24597375Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations
Q39859545Topical calcineurin inhibitors in eczema and cancer association: A cohort study
Q40122276Topical calcineurin inhibitors in systemic lupus erythematosus
Q37624689Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis
Q24186624Topical tacrolimus for atopic dermatitis
Q38419338Treatment of Eczema: Corticosteroids and Beyond
Q42708359Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

Search more.